206 related articles for article (PubMed ID: 9428829)
1. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
[TBL] [Abstract][Full Text] [Related]
2. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
Harris ST; Watts NB; Jackson RD; Genant HK; Wasnich RD; Ross P; Miller PD; Licata AA; Chesnut CH
Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
[TBL] [Abstract][Full Text] [Related]
3. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
[TBL] [Abstract][Full Text] [Related]
4. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
5. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
6. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
7. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
8. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
[TBL] [Abstract][Full Text] [Related]
9. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
10. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
[TBL] [Abstract][Full Text] [Related]
11. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
12. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Uzawa M
Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
14. Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.
Guañabens N; Farrerons J; Perez-Edo L; Monegal A; Renau A; Carbonell J; Roca M; Torra M; Pavesi M
Bone; 2000 Jul; 27(1):123-8. PubMed ID: 10865219
[TBL] [Abstract][Full Text] [Related]
15. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Diamond T; McGuigan L; Barbagallo S; Bryant C
Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
[TBL] [Abstract][Full Text] [Related]
16. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
[TBL] [Abstract][Full Text] [Related]
17. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
[TBL] [Abstract][Full Text] [Related]
18. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
Anderson FH; Francis RM; Bishop JC; Rawlings DJ
Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
[TBL] [Abstract][Full Text] [Related]
19. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
Sato S; Takada T; Katsuki Y; Kimura N; Kaneko Y; Suwa A; Hirakata M; Kuwana M
J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
[TBL] [Abstract][Full Text] [Related]
20. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
Montessori ML; Scheele WH; Netelenbos JC; Kerkhoff JF; Bakker K
Osteoporos Int; 1997; 7(1):52-8. PubMed ID: 9102064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]